Biological Evaluation of Maytansinoid-Based Site-Specific Antibody-Drug Conjugate Produced by Fully Chemical Conjugation Approach: AJICAP®
Takuya Seki(Suzuki (Japan)), Tatsuya Okuzumi(Suzuki (Japan)), Yutaka Matsuda(Ajinomoto (United States)), Brian A. Mendelsohn(Seagen (United States)), Yuri Ooba(Suzuki (Japan)), Kei Yamada(Hiroshima University), Tomohiro Fujii(Suzuki (Japan)), Yoshiro Kitahara(Nihon University), Takahiro Narita(Suzuki (Japan)), Akira Nakayama(Shizuoka University)
Cited by 8
Related Papers
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and Toxicity
|Bioconjugate Chemistry|2005|511
Inhibitor hijacking of Akt activation
|Nature Chemical Biology|2009|296
Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease.
|Circulation|1981|250
Repetitive Fluctuations in Blood Glucose Enhance Monocyte Adhesion to the Endothelium of Rat Thoracic Aorta
|Arteriosclerosis Thrombosis and Vascular Biology|2006|163